Positive News SentimentPositive NewsNASDAQ:OVID Ovid Therapeutics (OVID) Stock Price, News & Analysis → Your 'AI Income Playbook' Awaits... (From The Oxford Club) (Ad) Free OVID Stock Alerts $3.29 +0.09 (+2.81%) (As of 04:28 PM ET) Add Compare Share Share Today's Range$3.12▼$3.3150-Day Range$2.96▼$3.3452-Week Range$2.57▼$4.14Volume129,241 shsAverage Volume171,532 shsMarket Capitalization$233.39 millionP/E RatioN/ADividend YieldN/APrice Target$8.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ovid Therapeutics alerts: Email Address Ovid Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside145.7% Upside$8.08 Price TargetShort InterestBearish4.99% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$50,364 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.85) to ($0.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.29 out of 5 starsMedical Sector120th out of 917 stocksPharmaceutical Preparations Industry45th out of 431 stocks 3.4 Analyst's Opinion Consensus RatingOvid Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOvid Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Ovid Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.99% of the float of Ovid Therapeutics has been sold short.Short Interest Ratio / Days to CoverOvid Therapeutics has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.Change versus previous monthShort interest in Ovid Therapeutics has recently increased by 0.70%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOvid Therapeutics does not currently pay a dividend.Dividend GrowthOvid Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOvid Therapeutics has received a 71.15% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for Epilepsy or seizures" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Ovid Therapeutics is -0.85. Previous Next 3.8 News and Social Media Coverage News SentimentOvid Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Ovid Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for OVID on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ovid Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,364.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.30% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ovid Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ovid Therapeutics are expected to grow in the coming year, from ($0.85) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ovid Therapeutics is -4.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ovid Therapeutics is -4.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOvid Therapeutics has a P/B Ratio of 2.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ovid Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...Click here now to claim your FREE copy of Marc's AI playbook. About Ovid Therapeutics Stock (NASDAQ:OVID)Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Read More OVID Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OVID Stock News HeadlinesMay 28, 2024 | investorplace.com3 Sorry Penny Stocks to Sell in May While You Still CanMay 20, 2024 | markets.businessinsider.comBuy Rating for Ovid Therapeutics Based on Novel SE Drug Candidates OV329 and OV350May 20, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024May 16, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ovid Therapeutics Amid Strong Financials and Promising Drug PipelineMay 14, 2024 | investorplace.comOVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | globenewswire.comOvid Therapeutics Reports Business Updates and First Quarter 2024 Financial ResultsMay 13, 2024 | globenewswire.comOvid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 7, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For Ovid TherapeuticsApril 30, 2024 | nasdaq.comHC Wainwright & Co. Initiates Coverage of Ovid Therapeutics (OVID) with Buy RecommendationApril 18, 2024 | finance.yahoo.comWe Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business GrowthApril 5, 2024 | msn.comOvid Therapeutics gains on bullish view at WedbushApril 4, 2024 | globenewswire.comOvid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | msn.comMarinus Pharmaceuticals Stands Firm in Patent Dispute Over Key Epilepsy TreatmentMarch 29, 2024 | bizjournals.comMarinus Pharmaceuticals' patent battle with New York firm over seizure therapy takes new twistMarch 22, 2024 | investing.comOvid therapeutics CEO acquires $50k in company stockMarch 22, 2024 | finance.yahoo.comOvid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock BuyingMarch 17, 2024 | insidermonkey.com5 Oversold Biotech Stocks To Buy Right NowMarch 13, 2024 | markets.businessinsider.comOvid Therapeutics: Strong Buy Rating on Robust Pipeline and Strategic PartnershipsMarch 13, 2024 | news.yahoo.comOvid gas station, state and local officials dealing with contaminated fuel problemMarch 13, 2024 | msn.comOvid gas station shut down after discovery of water inside pumpsMarch 11, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)March 9, 2024 | finance.yahoo.comOVID Oct 2024 7.500 callMarch 8, 2024 | benzinga.comRecap: Ovid Therapeutics Q4 EarningsMarch 8, 2024 | globenewswire.comOvid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial ResultsSee More Headlines Receive OVID Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/14/2024Next Earnings (Estimated)8/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OVID CUSIPN/A CIK1636651 Webwww.ovidrx.com Phone(646) 661-7661FaxN/AEmployees40Year Founded2014Price Target and Rating Average Stock Price Target$8.08 High Stock Price Target$11.00 Low Stock Price Target$3.50 Potential Upside/Downside+152.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,340,000.00 Net Margins-10,691.14% Pretax Margin-10,691.35% Return on Equity-53.62% Return on Assets-37.76% Debt Debt-to-Equity Ratio0.18 Current Ratio10.47 Quick Ratio10.47 Sales & Book Value Annual Sales$390,000.00 Price / Sales582.07 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book2.58Miscellaneous Outstanding Shares70,940,000Free Float61,509,000Market Cap$227.01 million OptionableOptionable Beta0.58 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Jeremy Max Levin Ba Zoology (Age 71)Dphil, Mb Bchir, President, CEO & Chairman Comp: $1.03MMr. Jeffrey A. Rona (Age 56)Chief Business and Financial Officer Comp: $761.24kMr. Thomas Michael Perone J.D. (Age 59)M.B.A., General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $745.71kMr. Jason Tardio M.B.A. (Age 47)Chief Operating Officer Comp: $652.84kMr. Simon D. Kelner (Age 50)Chief Human Resources Officer Dr. Dirk Haasner (Age 59)Senior Vice President of Global Manufacturing & CMC QA Comp: $416.95kDr. Todd F. Baumgartner M.D.M.P.H., Senior Vice President of Regulatory AffairsDr. Julia Tsai Ph.D. (Age 49)Senior Vice President of Clinical Development Ms. Meg AlexanderChief Strategy OfficerDr. Manoj Malhotra M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsImmunicNASDAQ:IMUXBioDelivery Sciences InternationalNASDAQ:BDSIArcturus TherapeuticsNASDAQ:ARCTARS PharmaceuticalsNASDAQ:SPRY89bioNASDAQ:ETNBView All CompetitorsInsiders & InstitutionsBVF Inc. ILSold 2,997,233 shares on 5/16/2024Ownership: 5.442%Price T Rowe Associates Inc. MDBought 3,145 shares on 5/15/2024Ownership: 0.025%Vanguard Group Inc.Sold 13,469 shares on 5/10/2024Ownership: 4.203%Empowered Funds LLCBought 9,625 shares on 5/7/2024Ownership: 0.181%SG Americas Securities LLCSold 3,854 shares on 5/7/2024Ownership: 0.051%View All Insider TransactionsView All Institutional Transactions OVID Stock Analysis - Frequently Asked Questions Should I buy or sell Ovid Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OVID shares. View OVID analyst ratings or view top-rated stocks. What is Ovid Therapeutics' stock price target for 2024? 6 Wall Street analysts have issued 1-year target prices for Ovid Therapeutics' stock. Their OVID share price targets range from $3.50 to $11.00. On average, they predict the company's stock price to reach $8.08 in the next year. This suggests a possible upside of 145.7% from the stock's current price. View analysts price targets for OVID or view top-rated stocks among Wall Street analysts. How have OVID shares performed in 2024? Ovid Therapeutics' stock was trading at $3.22 at the beginning of 2024. Since then, OVID shares have increased by 2.2% and is now trading at $3.29. View the best growth stocks for 2024 here. When is Ovid Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 2nd 2024. View our OVID earnings forecast. How were Ovid Therapeutics' earnings last quarter? Ovid Therapeutics Inc. (NASDAQ:OVID) posted its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.06. The company had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.11 million. Ovid Therapeutics had a negative net margin of 10,691.14% and a negative trailing twelve-month return on equity of 53.62%. What other stocks do shareholders of Ovid Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX). When did Ovid Therapeutics IPO? Ovid Therapeutics (OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers. Who are Ovid Therapeutics' major shareholders? Ovid Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BVF Inc. IL (5.44%), Vanguard Group Inc. (4.20%), Empowered Funds LLC (0.18%), Assenagon Asset Management S.A. (0.16%), SG Americas Securities LLC (0.05%) and BNP Paribas Financial Markets (0.05%). Insiders that own company stock include Amit Rakhit, Jason Tardio and Jeremy M Levin. View institutional ownership trends. How do I buy shares of Ovid Therapeutics? Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OVID) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersPresident KamalaThe sneaky (yet 100% legal) way for Obama to return to power The ONLY way Democrats can keep the White Hous...Stansberry Research | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.